Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Cancers|July 24, 2021
New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ SignalingMichal Mahdal, Jakub Neradil, Peter Mudry, et al.BMC Cancer|February 11, 2017
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB genePeter Mudry, Ondrej Slaby, Jakub Neradil, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 22, 2016
Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient miceJan Skoda, Alena Nunukova, Tomas Loja, et al.Cellular Oncology (Dordrecht, Netherlands)|December 4, 2024
Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traitsLucie Curylova, Iva Staniczkova Zambo, Jakub Neradil, et al.Analytical Cellular Pathology (Amsterdam)|December 14, 2011
CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell linesJiri Sana, Iva Zambo, Jan Skoda, et al.Frontiers in Oncology|August 6, 2019
Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life ScenarioMichal Kyr, Kristyna Polaskova, Zuzana Kuttnerova, et al.Journal of Neuro-Oncology|July 8, 2010
Low-level copy number changes of MYC genes have a prognostic impact in medulloblastomaKarel Zitterbart, Hana Filkova, Lenka Tomasikova, et al.Cancer Letters|January 22, 2019
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastomaSara Gomes, Liliana Raimundo, Joana Soares, et al.Pediatric Blood & Cancer|October 25, 2021
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumorAndrew D Woods, Noah E Berlow, Michael V Ortiz, et al.Cell Reports|April 14, 2021
A selective p53 activator and anticancer agent to improve colorectal cancer therapyHelena Ramos, Maria I L Soares, Joana Silva, et al.Pageof 6